Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Fish and Richardson
McKesson
Express Scripts
Fuji
Boehringer Ingelheim
Cipla
Cantor Fitzgerald
Queensland Health
Healthtrust

Generated: January 21, 2018

DrugPatentWatch Database Preview

Tripelennamine hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for tripelennamine hydrochloride and what is the scope of tripelennamine hydrochloride patent protection?

Tripelennamine hydrochloride
is the generic ingredient in three branded drugs marketed by Novartis, Anabolic, Barr, Heather, Impax Labs, Lannett, Nylos, Parke Davis, and Watson Labs, and is included in fourteen NDAs. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for tripelennamine hydrochloride.
Summary for tripelennamine hydrochloride

US Patents and Regulatory Information for tripelennamine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Parke Davis TRIPELENNAMINE HYDROCHLORIDE tripelennamine hydrochloride TABLET;ORAL 083626-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lannett TRIPELENNAMINE HYDROCHLORIDE tripelennamine hydrochloride TABLET;ORAL 083557-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Novartis PBZ-SR tripelennamine hydrochloride TABLET, EXTENDED RELEASE;ORAL 010533-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Watson Labs TRIPELENNAMINE HYDROCHLORIDE tripelennamine hydrochloride TABLET;ORAL 080790-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Heather TRIPELENNAMINE HYDROCHLORIDE tripelennamine hydrochloride TABLET;ORAL 083989-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Novartis PBZ tripelennamine hydrochloride TABLET;ORAL 005914-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Nylos TRIPELENNAMINE HYDROCHLORIDE tripelennamine hydrochloride TABLET;ORAL 085412-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Novartis PBZ-SR tripelennamine hydrochloride TABLET, EXTENDED RELEASE;ORAL 010533-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Barr TRIPELENNAMINE HYDROCHLORIDE tripelennamine hydrochloride TABLET;ORAL 080744-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Watson Labs TRIPELENNAMINE HYDROCHLORIDE tripelennamine hydrochloride TABLET;ORAL 085188-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
US Army
Chinese Patent Office
Baxter
McKesson
Johnson and Johnson
Dow
Healthtrust
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot